1. Home
  2. ECPG vs ANIP Comparison

ECPG vs ANIP Comparison

Compare ECPG & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Encore Capital Group Inc

ECPG

Encore Capital Group Inc

HOLD

Current Price

$70.86

Market Cap

1.4B

Sector

Finance

ML Signal

HOLD

ANIP

ANI Pharmaceuticals Inc.

HOLD

Current Price

$74.08

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ECPG
ANIP
Founded
1998
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.7B
IPO Year
1999
1999

Fundamental Metrics

Financial Performance
Metric
ECPG
ANIP
Price
$70.86
$74.08
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$77.33
$110.00
AVG Volume (30 Days)
291.9K
330.9K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
287.14
419.23
EPS
10.91
3.32
Revenue
$1,768,802,000.00
$206,547,000.00
Revenue This Year
$4.53
$23.05
Revenue Next Year
$4.76
$14.08
P/E Ratio
$6.48
$22.09
Revenue Growth
34.37
2.47
52 Week Low
$26.45
$56.71
52 Week High
$74.58
$99.50

Technical Indicators

Market Signals
Indicator
ECPG
ANIP
Relative Strength Index (RSI) 63.94 44.96
Support Level $54.39 $71.29
Resistance Level $74.58 $84.47
Average True Range (ATR) 2.35 2.37
MACD -0.12 0.19
Stochastic Oscillator 79.96 51.02

Price Performance

Historical Comparison
ECPG
ANIP

About ECPG Encore Capital Group Inc

Encore Capital Group Inc is an international specialty finance company engaged in providing debt recovery solutions and other related services for consumers across a broad range of financial assets. It mainly purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals to repay their obligations and work toward financial recovery. The company also provides debt servicing and other portfolio management services to credit originators for non-performing loans in Europe. It has only one reportable segment, debt purchasing and recovery. Geographically, the company generates maximum revenue from its business in the United States, followed by the United Kingdom, Europe, and other regions.

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

Share on Social Networks: